Saeed Kahkeshani, MD
Neurodevelopmental Disabilities · Baytown, TXNPI 1417006313
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,049, more than ten times the $37 reported in 2019.
Across 144 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$423
- Eisai Inc.$381
- SK Life Science, Inc.$254
- Argenx US, Inc.$253
- AbbVie$231
- Biogen$184
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,953100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $423 |
| Eisai Inc. | 19 | $381 |
| SK Life Science, Inc. | 10 | $254 |
| Argenx US, Inc. | 10 | $253 |
| AbbVie | 13 | $231 |
| Biogen | 9 | $184 |
| Neurocrine Biosciences, Inc. | 7 | $142 |
| Acadia Pharmaceuticals Inc | 5 | $97 |
| Mallinckrodt Hospital Products Inc. | 3 | $94 |
| Corium, LLC | 3 | $93 |
| Sumitomo Pharma America, Inc. | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 2 | $61 |
| AstraZeneca(2 entities) | 4 | $56 |
| Harmony Biosciences LLC | 2 | $56 |
| Lundbeck LLC | 3 | $55 |
| Boston Scientific | 2 | $52 |
| UCB, Inc. | 1 | $40 |
| Livanova USA, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Aucta Pharmaceuticals, Inc. | 3 | $31 |
| Genentech USA, Inc. | 2 | $29 |
| Sanofi | 1 | $28 |
| Kedrion Biopharma, Inc. | 1 | $24 |
| MDD US Operations, LLC | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $21 |
| Pfizer | 1 | $21 |
| GE HealthCare | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
Too few neurodevelopmental disabilities providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 24 | $206,938 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $136,337 |
| Aimovig AutoinjectorErenumab-Aooe | 38 | $33,224 |
| AptiomEslicarbazepine Acetate | 17 | $30,094 |
| XcopriCenobamate | 19 | $15,376 |
| FycompaPerampanel | 11 | $13,586 |
| Levetiracetam | 316 | $12,071 |
| EliquisApixaban | 11 | $10,324 |
| Memantine Hcl | 628 | $10,092 |
| BrilintaTicagrelor | 16 | $7,112 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 203 | $6,789 |
| Oxcarbazepine | 82 | $6,540 |
| Lacosamide | 53 | $6,377 |
| Pyridostigmine Bromide | 28 | $6,110 |
| AdlarityDonepezil Hcl | 12 | $5,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $184 | $206,93824 claims |
| SK Life Science, Inc.Xcopri | $254 | $15,37619 claims |
| Eisai Inc.Fycompa | $381 | $13,58611 claims |
| PfizerEliquis | $21 | $10,32411 claims |
| AstraZenecaBrilinta | $56 | $7,11216 claims |
| Corium, LLCAdlarity | $93 | $5,25812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurodevelopmental disabilities providers in Texason file to place this against a meaningful peer group, so we don't.
Other neurodevelopmental disabilities in Baytown
- Rafael MimbelaDonna$10K
- Satish AgadiGalveston$8K
- Rafael Villalobos-NietoHarlingen$8K
- Uloma LabrieDallas$2K
- Pamela LupoWebster$2K
- Linda NguyenDallas$526
- Vanessa Caress Mbanga TchakountePasadena$319
- Katrina Willie-MusomaMansfield$172
- Pauline FilipekHouston$168
- Sangeeta ElhenceFort Worth$100
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.